$THC

KERREY J ROBERT sold $294K of THC

KERREY J ROBERT sold 1,690 shares of TENET HEALTHCARE CORP (THC) at $173.97 ($0.29M total) on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

This disclosure may modestly affect short-term sentiment toward Tenet Healthcare, but it does not provide new company performance or outlook information.

02

Market read

A director’s open-market sale worth ~$294K is a small, sentiment-oriented datapoint for THC.

03

What to watch

Insider sales can be scheduled for tax/financial planning, and the absence of a stated 10b5-1 plan does not confirm opportunistic trading or negative fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 for a sale executed 2026-05-28

Background

SEC Form 4 discloses insider transactions by directors/officers/10% owners; these are typically monitored for sentiment but are not equivalent to earnings or guidance changes.

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 1,690 shares in an open-market transaction worth about $294K, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional insider selling or company-specific news.

Evidence & confidence

Form 4 insider sales are common and often non-informational; however, the director’s sale can slightly increase perceived risk, especially because the filing notes no pre-arranged 10b5-1 plan.

Market effects

Minimal—single-company insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; without evidence of broader selling or operational issues, price impact may be negligible.

Key entities

  • Tenet Healthcare Corp

    Subject of the insider sale disclosure; director sold 1,690 shares at ~$173.97 on 2026-05-28.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.